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Background
Pregnant women experience physiological changes dur-
ing pregnancy resulting in clinically significant altera-
tions in antiretroviral pharmacokinetics (PK). Therefore,
achieving and maintaining optimal plasma concentra-
tions of antiretroviral drugs is essential for maternal
health and minimising the risk of mother-to-child trans-
mission of HIV.
Purpose of the study
To describe atazanavir/ritonavir (ATV/r) PK during
pregnancy.
Methods
In this prospective, open labelled study, pregnant HIV-
positive women received ATV/r as part of their routine
pre-natal care. Demographic and clinical data were col-
lected, and ATV plasma concentrations [ATV] were
determined in the first (T1) and/or second (T2) and/or
third (T3) trimester using HPLC-MS/MS (LLQ = 0.05
µg/mL). Postpartum (PP) sampling was performed where
applicable. Antepartum (AP) and PP PK parameters were
compared using a One-way ANOVA (for independent
data sets) and a paired t-test (for paired data).
Summary of results
From January 2007 31 women (25 black African) were
enrolled in the study. All received ATV/r at standard
dose of 1 tablet once daily (300/100 mg od). 10/31
women initiated ATV/r treatment during pregnancy.
Median (range) gestation at initiation in these patients
was 24 weeks (7-35). Median (range) baseline CD4
count was 393 cells/µL (153-869) and 17 patients had a
baseline plasma viral load of < 50 copies/mL. [ATV]
were determined in 10/31 (T1); 17/31 (T2); 27/31 (T3)
and 21/31 (PP) patients. Time of TDM sampling and
[ATV] (geometric mean; 95%CI) are given in the Table.
2/17 patients at T2, 2/27 (T3) and 2/21 at PP had con-
centrations <LLQ (suggesting non-adherence). [ATV]
were lower AP relative to that observed at PP (Table 1).
Equally, in a paired analysis of 17 patients (T3 vs. PP),
[ATV] were significantly reduced at T3 (P=0.0005).
Conclusions
Although ATV concentrations were reduced in the third
trimester, standard ATV/r dosing did achieve therapeu-
tic levels (>150 ng/mL) both antepartum and postpar-
tum, suggesting the current regimen is appropriate in
pregnancy.
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Table 1
T1 (n=10) T2 (n=17) T3 (n=27) PP (n=21) P value
[ATV], µg/mL 1.03 (0.49-2.53) 0.75 (0.59-1.45) 0.66 (0.63-1.03) 1.17 (1.09-1.81) 0.06
CV, % 108 84 59 55 -
Time of sampling, h 14.6 (12.5-17.5) 18.0 (16-21.8) 19.0 (17.6-21.9) 19.1 (17.4-22.3) 0.102
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